UNSPSC 51321903: Efaproxiral

This classification denotes a radiosensitizing agent with the molecular formula C20H23NO4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier J81E81G364, chemically known as 2-(4-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2 methylpropanic acid but more generally known as efaproxiral, which bears U.S. NIH Compound Identifier 122335. European Medicines Agency schedules Efaproxiral in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21811.

The term EFAPROXIRAL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3, 2002, List 48). World Health Organization schedules efaproxiral in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.

UNSPSC 51321903 Efaproxiral, a Commodity code, covers emergency medications and specialty pharmaceuticals procured by state and local health agencies and first responder departments. State and local governments acquire these products for emergency medical services, hospital systems, and public health programs — sourced through direct vendor contracts, authorized wholesalers, and cooperative purchasing agreements. The issuing bodies span city fire rescue departments, state health agencies, and multistate cooperative purchasing alliances; Tampa Fire Rescue and the Texas Health and Human Services Commission and Minnesota Department of Administration represent the mix of end-use and administrative buyers active under this code.

Recent activity clusters in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (response deadline April 8, 2026, estimated value $40,000) supplying Labetalol, Epinephrine, Adenosine, and Diltiazem vials to Tampa Fire Rescue with nine-month minimum expiration dates and firm pricing including freight to Tampa. The Texas HHS Commission posted RFI HHS0017013 (response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (administered by Minnesota Department of Administration) issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and contract terms of two years. Competitive access under recent solicitations has included SLBE sheltered-market designations with bid discounts (Tampa), cGMP and DSCSA compliance requirements, and pricing flexibility through net pricing and WAC-minus models (Minnesota cooperative).